The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer

BMC Cancer

Research Article

Tetsuro Ikeya¹  Kiyoshi Maeda¹  Kenji Sugano¹  Yasuhito Iseki¹  Hisashi Nagahara¹  Masatsune Shibutani¹  Kosei Hirakawa¹  Hiroshi Ohtani¹ 

[1] Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4–3 Asahi-machi Abeno–ku, Osaka, Japan;

关键词: Colorectal cancer;    Prognosis;    Unresectable;    Chemotherapy;    Albumin to globulin ratio;   

DOI  :  10.1186/s12885-015-1375-x

 received in 2014-12-04, accepted in 2015-04-27,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundThe pretreatment albumin to globulin ratio (AGR) has been reported to correlate with the long-term survival in patients with various cancers. However, there are no reports regarding the correlation between the pretreatment AGR and chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. The aim of this study was to evaluate the prognostic significance of the pretreatment AGR in patients with unresectable metastatic colorectal cancer.MethodsA total of 66 patients with unresectable metastatic colorectal cancer who underwent palliative chemotherapy for metastatic tumors were enrolled. The AGR was calculated as follows: Albumin/(Total protein - Albumin).ResultsThe median pretreatment AGR was 1.254 (range: 0.849-1.840). We set 1.25 as the cut-off value based on the receiver operating characteristic curve. Based on the cut-off value of 1.25, 34 patients were classified into the high-AGR group and 32 patients were classified into the low-AGR group. The high-AGR group had a significantly higher chemotherapeutic disease control rate (p = 0.040) and better progression-free survival (p = 0.0171) and overall survival (p = 0.0360) rates than the low-AGR group. According to a multivariate analysis of survival, the AGR was identified to be an independent prognostic factor for progression-free survival (Hazard Ratio: 2.662, 95% Confidence Interval: 1.085-6.631, p = 0.033) and overall survival (Hazard Ratio: 2.247, 95% Confidence Interval: 1.069-4.722, p = 0.033).ConclusionsThe pretreatment AGR is a useful prognostic marker in patients with unresectable metastatic colorectal cancer who receive palliative chemotherapy.

【 授权许可】

CC BY   
© Shibutani et al.; licensee BioMed Central. 2015